Clinical trial
A Randomised, Double Blinded, Placebo-controlled Single and Multiple Ascending Dose Study of Orally Administered RV299 to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect in Healthy Adult Participants
NCT06033612 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double Blinded, Placebo-controlled Single and Multiple Ascending Dose Study of Orally Administered RV299 to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect in Healthy Adult Participants
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 12, 2021
- Completion date
- July 27, 2022
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.